New blood thinner may offer better stroke protection for rare clotting disorder

NCT ID NCT03684564

First seen Jun 02, 2026 · Last updated Jun 13, 2026 · Updated 2 times

Summary

This study tested two blood thinners, rivaroxaban and warfarin, in 43 people with antiphospholipid syndrome (APS) who had a stroke. The goal was to see which drug better prevents further brain damage over 24 months. Participants took either rivaroxaban twice daily or warfarin daily. The trial used brain scans to measure changes in small blood vessel damage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Barts and the London Hospitals, Barts Health NHS Trust

    London, United Kingdom

  • Epsom and St Helier University Hospitals NHS Trust

    Epsom, United Kingdom

  • Hammersmith Hospital, Imperial College Healthcare NHS Trust

    London, United Kingdom

  • Kings College Hospital NHS Foundation Trust

    London, United Kingdom

  • Queens Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust

    Romford, United Kingdom

  • University College Hospitals NHS Foundation Trust

    London, United Kingdom

Conditions

Explore the condition pages connected to this study.